| Not Yet Recruiting | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer NCT07383441 | SWOG Cancer Research Network | Phase 3 |
| Not Yet Recruiting | Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer NCT07226544 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Cl NCT07516366 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Su NCT07037004 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell C NCT07510334 | Mayo Clinic | Phase 2 |
| Recruiting | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatm NCT07128680 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and M NCT06391099 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Ki NCT06866262 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer NCT06399419 | Osel, Inc. | Phase 1 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Active Not Recruiting | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell C NCT06049576 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study NCT05863351 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Active Not Recruiting | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 T NCT05411081 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With NCT05327686 | NRG Oncology | Phase 2 |
| Recruiting | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study NCT05361720 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Withdrawn | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma NCT04961320 | City of Hope Medical Center | N/A |
| Recruiting | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer NCT04981509 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer NCT04904302 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cel NCT05012371 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy NCT05112627 | Mayo Clinic | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer NCT04603365 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Ce NCT04788095 | City of Hope Medical Center | N/A |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Ki NCT04510597 | SWOG Cancer Research Network | Phase 3 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Terminated | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery NCT04370509 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | Cancer and Blood Pressure Management, CARISMA Study NCT04467021 | ECOG-ACRIN Cancer Research Group | N/A |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal C NCT04393350 | Emory University | Phase 2 |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Active Not Recruiting | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients NCT03793166 | National Cancer Institute (NCI) | Phase 3 |
| Completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer NCT03829111 | City of Hope Medical Center | Phase 1 |
| Recruiting | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 NCT03284385 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT03587662 | M.D. Anderson Cancer Center | Phase 2 |
| Suspended | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma NCT03575611 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer NCT03473730 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcino NCT03541902 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma NCT03274258 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |